Anavex Life Sciences Corp (AVXL)

[imho]

So the first part of the trial will probably be open label so patients can be closely monitored for signs of side effects in an effort to determine MTD for Rett patients. The inter-patient variability and the age related variability in drug clearance are probably why the FDA is requiring the 15 patient study first.

Thanks F1ash. That seems right.

IMHO